RFL
What one share of Rafael Holdings holds
Pharmaceutical Preparations
Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (“NPC1”),
Rafael Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-04-30; the balance sheet is as of 2026-04-30.
| Sales | $0.02 |
|---|---|
| Profit | −$0.66 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.65 |
| Cash and investments | $0.60 |
| Debt | $0.01 |
| Book value | $1.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.45 | $0.06 | $0.12 | −$0.12 | — | $3.91 |
| 2017 | $0.45 | $0.01 | $0.15 | −$0.28 | — | $4.22 |
| 2018 | $0.35 | −$0.93 | $0.06 | −$0.20 | — | $8.55 |
| 2019 | $0.37 | −$0.35 | $0.03 | −$0.27 | — | $8.36 |
| 2020 | $0.31 | −$0.66 | $0.03 | −$0.33 | — | $7.41 |
| 2021 | $0.05 | −$1.49 | $0.01 | −$0.96 | — | $7.40 |
| 2022 | $0.02 | −$6.31 | $0.00 | −$1.32 | — | $5.08 |
| 2023 | $0.01 | −$0.08 | — | −$0.47 | — | $4.31 |
| 2024 | $0.03 | −$1.45 | $0.01 | −$0.33 | — | $3.46 |
| 2025 | $0.03 | −$1.04 | $0.00 | −$0.64 | — | $3.21 |